Helicobacter pylori-related diseases

Area of Science:

• Gastroenterology
• Infectious Diseases
• Microbiology

Background:

• Helicobacter pylori (H. pylori) infection prevalence is decreasing globally but remains high in developing countries.
• Antibiotic resistance to clarithromycin, metronidazole, and quinolones is increasing worldwide.
• Current H. pylori management, particularly for peptic ulcers, requires improvement, and eradication does not fully prevent gastric adenocarcinoma.

Purpose of the Study:

• To summarize key findings and treatment recommendations for H. pylori infection presented at Digestive Diseases Week 2016.
• To highlight challenges in H. pylori eradication due to rising antibiotic resistance.
• To evaluate the efficacy of novel and established treatment regimens.

Main Methods:

• Review of presentations and discussions from Digestive Diseases Week 2016 focusing on H. pylori infection.
• Analysis of current data on H. pylori prevalence, antibiotic resistance patterns, and treatment outcomes.
• Comparison of different therapeutic strategies, including standard triple therapy, quadruple therapy, and vonoprazan-based regimens.

Main Results:

• Standard triple therapy for H. pylori eradication is increasingly ineffective and no longer recommended.
• Vonoprazan-based regimens show superior efficacy compared to traditional proton pump inhibitors, especially in clarithromycin-resistant cases.
• Non-bismuth quadruple (concomitant) therapy achieves approximately 90% eradication rates and is more effective and simpler than sequential therapy.
• Rescue therapies combining bismuth with levofloxacin improve eradication rates after initial treatment failure.
• Significant heterogeneity exists in European clinical practice, with generally unacceptable eradication rates.

Conclusions:

• Effective H. pylori eradication requires moving beyond standard triple therapy due to widespread antibiotic resistance.
• Non-bismuth quadruple (concomitant) therapy and vonoprazan-based regimens represent more effective first-line and salvage treatment options.
• Addressing the gap between clinical guidelines and primary care practice is crucial for improving H. pylori management outcomes.